Embolism/thrombosis
Head-to-head: Surgical embolectomy versus ultrasound-assisted thrombolysis in high-risk pulmonary embolism
NOAH-AFNET 6: Does the duration of AHRE influence response to edoxaban?
ARTESIA: How useful is anticoagulation in subclinical AF?
Edoxaban versus warfarin in chronic thromboembolic pulmonary hypertension
Should we use anticoagulation in AHRE to prevent stroke?
Results of FRAIL-AF trial suggest increased bleeding risk with DOACs
Guidelines for Acute Coronary Syndrome
The optimal duration of anticoagulation therapy in cancer patients with DVT
How to manage arterial thrombosis and thromboembolism in COVID-19?
New analysis assesses the safety of tofacitinib regarding extended MACE
Head-to-head: post-TAVR edoxaban not better than DAPT
Post-pulmonary embolism impairment frequent, follow-up urged after acute PE
Milvexian phase 2 data supports safety and efficacy for VTE prevention after total knee replacement
Support for adapted D-dimer thresholds for ruling out pulmonary embolism
Apixaban tops rivaroxaban for repeat-VTE protection in real-world analysis
Psoriasis tied to small increase in risk of venous thromboembolism, peripheral vascular disease
Recurrent VTE more common than thought with isolated subsegmental pulmonary embolism
Increased risk of cerebral venous thrombosis in COVID-19
Rivaroxaban improves clinical outcomes in discharged COVID-19 patients
COVID-19: Thromboembolic risk reduction with therapeutic heparin dosing
‘Considerable’ bleeding risk with extended anticoagulant therapy after first unexplained VTE
Early switch to DOAC appears safe and effective for intermediate-risk pulmonary embolism
Physiopathology of coagulopathy in haematological malignancies and COVID-19
Haemostatic abnormalities are associated with mortality in COVID-19
COVID-19 vaccine-induced immune thrombotic thrombocytopenia: discovery and diagnosis
Factor XI inhibitor cuts risk of postoperative venous thromboembolism by about 80%
Genotype-based strategy reduces thrombotic events after heart-device implant
Therapeutic anticoagulation not superior to prophylactic anticoagulation in COVID-19
Atorvastatin does not reduce mortality in COVID-19
Many patients on DOACs receive concurrent non-indicated aspirin tied to bleeding risk
PCSK9 inhibition as primary prevention for VTE: Is it LDL or Lp(a)?
Similar outcomes sPESI and HESTIA for pulmonary embolism triage
Risk factors for thromboembolism and bleeding in COVID-19: lessons from Wuhan
DVT screening, early treatment, prevent PE in necrotizing pancreatitis
Physical rehabilitation improves health outcomes after pulmonary embolism
Residual pulmonary obstruction may predict risk of VTE recurrence
Risk of checkpoint inhibitor-associated thromboembolic events important for cancer prognosis
COVID-19 associated with higher VTE rates relative to influenza
Therapeutic anticoagulation not associated with lower mortality rates in COVID-19 ICU patients
COVID-19 not associated with heightened VTE risk after discharge
Higher thrombotic risk in NSCLC patient with ALK rearrangement
